Patients hospitalized for COVID-19 may experience after-effects of the condition 3 months post-discharge, according to a study from The Netherlands.
Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.
Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.
Final analysis of the phase III TITAN* trial, presented at ASCO GU 2021, has shown that the addition of apalutamide to androgen deprivation therapy (ADT) improves overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
In patients with metastatic colorectal cancer (mCRC), the addition of anlotinib to best supportive care did not confer overall survival (OS) benefit, though there was improvement in progression-free survival (PFS), according to results of the phase III ALTER0703 trial presented at ASCO GI 2021.
Daily doses of baclofen may help reduce the risk of agitation among individuals with unhealthy alcohol use admitted to the intensive care unit (ICU), according to results of the BACLOREA* trial presented at eCCR 2021.